Filter the drugs by the phase of research, how they help and the responsive mutations.
Cystic fibrosis is a genetic disease caused by mutations in the CFTR gene. Browse the
database of
drugs treating specific mutations compiled by the AIM tool.
| Drug | Marketed as | Description | Phase of research | How it helps |
|---|---|---|---|---|
| STAT1 | CFTR corrector |
Pre-clinical | Restore CFTR Function | |
| TCP10L | CFTR corrector |
Pre-clinical | Restore CFTR Function | |
| TFG | CFTR corrector |
Pre-clinical | Restore CFTR Function | |
| TMA | CFTR corrector and potentiator |
Pre-clinical | Restore CFTR Function | |
| Thymosin α1 | ZADAXIN™ | Natural polypeptide reducing inflammation and increasing CFTR maturation, stability and activity |
Therapeutic not approved by FDA or EMA | Restore CFTR Function + Anti-Inflammatory |
| VX-152 | CFTR corrector |
Phase Two Clinical Trial | Restore CFTR Function | |
| VX-440 | CFTR corrector |
Phase Two Clinical Trial | Restore CFTR Function | |
| VX-659 | CFTR corrector |
Phase Two Clinical Trial | Restore CFTR Function | |
| Vancomycin | AeroVanc™ | Antimicrobial activity |
Phase Three Clinical Trial | Anti-Infective |
| Veliparib | PARP-1 inhibitor able to partially restore CFTR channel activity |
Pre-clinical | Restore CFTR Function |
